Hjem › Lungekreft › Pennsylvania › Reading
Kliniske studier for Lungekreft i Reading, PA
11 studier for Lungekreft søker deltakere på steder i og rundt Reading (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruttererFase 3
- Reading Hospital, West Reading · 1 mi unna
- Ephrata Cancer Center, Ephrata · 17 mi unna
- Sechler Family Cancer Center, Lebanon · 26 mi unna
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Penn State Health Saint Joseph Medical Center, Reading
- Reading Hospital, West Reading · 1 mi unna
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
RekruttererFase 3
- Reading Hospital, West Reading · 1 mi unna
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RekruttererFase 3
- Ephrata Cancer Center, Ephrata · 17 mi unna
- Sechler Family Cancer Center, Lebanon · 26 mi unna
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekruttererFase 3
- Reading Hospital, West Reading · 1 mi unna
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RekruttererFase 3
- Reading Hospital - McGlinn Cancer Institute, West Reading · 1 mi unna
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
RekruttererFase 3
- Reading Hospital, West Reading · 1 mi unna
- Ephrata Cancer Center, Ephrata · 17 mi unna
- Sechler Family Cancer Center, Lebanon · 26 mi unna
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruttererFase 2
- Ephrata Cancer Center, Ephrata · 17 mi unna
- Sechler Family Cancer Center, Lebanon · 26 mi unna
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- Ephrata Cancer Center, Ephrata · 17 mi unna
- Sechler Family Cancer Center, Lebanon · 26 mi unna
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2/3
- Ephrata Cancer Center, Ephrata · 17 mi unna
- Sechler Family Cancer Center, Lebanon · 26 mi unna
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
RekruttererObservasjonsstudie
- US Digestive Health at Wyomissing, Wyomissing · 2 mi unna
Lungekreft-studier i andre byer
- Houston, TX78 studier
- Boston, MA62 studier
- New York City, NY60 studier
- Los Angeles, CA45 studier
- Washington, DC41 studier
- Arlington, VA41 studier
- Chicago, IL41 studier
- Nashville, TN40 studier
- Baltimore, MD40 studier
- St. Louis, MO39 studier
- Columbus, OH37 studier
- Philadelphia, PA36 studier
Andre studier i Reading
- Ikke-småcellet lungekreft9 studier
- Akut myelogen leukemi5 studier
- Brystkreft5 studier
- Sykdommer med overdreven søvnighet5 studier
- Prostatakreft4 studier
- Kreft (alle typer)4 studier
- Kolorektal kreft3 studier
- Narkolepsi3 studier
- Søvnforstyrrelser3 studier
- Trøtthet3 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.